檢索結果 - Shebl, Amgad

Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study 由 Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

獲取全文 獲取全文 獲取全文

Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US 由 Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

獲取全文 獲取全文 獲取全文

Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... 由 Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

獲取全文 獲取全文 獲取全文

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme 由 Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

獲取全文 獲取全文 獲取全文

Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... 由 Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

獲取全文 獲取全文 獲取全文

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... 由 Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

獲取全文 獲取全文 獲取全文